口服减重药数据不及预期 礼来股价重挫逾14%

Core Viewpoint - Eli Lilly's stock experienced a significant drop of over 14% during intraday trading on August 7, following the release of clinical trial results that did not meet market expectations [2]. Group 1: Clinical Trial Results - Eli Lilly announced clinical data for its oral weight loss drug Orforglipron, which was tested on over 3,000 overweight adults with at least one weight-related comorbidity but without diabetes [2]. - In the highest dosage group, participants achieved an average weight loss of 12.4 kg over 72 weeks, translating to a weight reduction of 12.4% [2].